GlassScriptPhysician profile
Gaja Andzel
NPI 1821231648
$111,141.88
in general payments reported to CMS, 2019-2025
34 companies · $29K in 2025
The $29K reported for 2025 was more than what 94% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,618 · 2020: $5,335 · 2021: $17K · 2022: $16K · 2023: $18K · 2024: $25K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Honoraria: $18K · Travel and Lodging: $4,680 · Food and Beverage: $3,371 · Consulting Fee: $2,340 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,700.00 |
| Honoraria | $18,260.00 |
| Travel and Lodging | $4,679.90 |
| Food and Beverage | $3,371.31 |
| Consulting Fee | $2,340.00 |
| Education | $194.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $84,211.69 | 2019-2025 | Korlym |
| Mannkind Corporation | $11,389.66 | 2019-2022 | |
| Abbott Laboratories | $9,015.33 | 2019-2022 | |
| Novo Nordisk INC | $3,139.21 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $521.63 | 2019-2022 | |
| Amgen INC. | $360.28 | 2019-2025 | Tepezza |
| Lilly USA, LLC | $335.49 | 2019-2024 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $302.50 | 2019-2021 | |
| Amarin Pharma, INC. | $280.31 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $134.61 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $131.08 | 2020-2022 | |
| Insulet Corporation | $126.52 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $124.99 | 2022 | |
| Genzyme Corporation | $105.00 | 2019 | |
| Merck Sharp & Dohme LLC | $100.89 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Companion Medical, INC. | $97.45 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $92.82 | 2019-2022 | |
| Radius Health, INC. | $72.94 | 2020-2022 | |
| Lifescan, INC. | $72.41 | 2020-2022 | |
| Therapeuticsmd, INC. | $63.98 | 2019-2020 | |
| Ibsa Pharma INC. | $58.46 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $56.66 | 2019 | |
| Abbvie INC. | $48.13 | 2019-2020 | |
| Dexcom, INC. | $46.60 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.33 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.33 | 2020 | |
| Horizon Therapeutics Plc | $38.84 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $35.54 | 2019 | |
| Janssen Pharmaceuticals, INC | $31.88 | 2019 | |
| Amryt Pharma Holdings LTD | $18.35 | 2020 | |
| Astellas Pharma US INC | $16.48 | 2020 | |
| Recordati_rare_diseases_inc. | $13.92 | 2021 | |
| Currax Pharmaceuticals LLC | $12.74 | 2020 | |
| Travere Therapeutics, INC. | $0.83 | 2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gaja Andzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.